4,5-dimethyl-2-nitrofluoroacetanilide | 774582-58-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,5-dimethyl-2-nitrofluoroacetanilide
• 英文别名: N-(2-benzyloxy-4-bromo-6-nitro-phenyl)-2,2,2-trifluoroacetamide；N-(2-Benzyloxy-4-bromo-6-nitro-phenyl)-2,2,2-trifluoro-acetamide；N-(4-bromo-2-nitro-6-phenylmethoxyphenyl)-2,2,2-trifluoroacetamide
• CAS: 774582-58-0
• 化学式: C₁₅H₁₀BrF₃N₂O₄
• 分子量: 419.155
• InChiKey: DAZRALXJRROGEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4,5-dimethyl-2-nitrofluoroacetanilide 在 镍 silica gel 、 petroleum ether ethyl acetate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以to afford 30.6 g (58%) of the title compound as a beige solid的产率得到4-benzyloxy-6-bromo-2-trifluoromethyl-benzimidazol-1-ol
  参考文献：
  名称：

  Cyclic benzimidazoles

  摘要：

  本发明涉及制备环状苯并咪唑的方法，所述化合物具有抑制胃分泌和优异的胃肠保护作用性能。

  公开号：

  US20080113963A1
• 作为产物：
  描述：

  4-溴-2-硝基-6-苯基甲氧基苯胺 、 三氟乙酸酐 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以83%的产率得到4,5-dimethyl-2-nitrofluoroacetanilide
  参考文献：
  名称：

  [EN] CYCLIC BENZIMIDAZOLES
  [FR] BENZIMIDAZOLES CYCLIQUES

  摘要：

  该发明涉及公式（1）中的环状苯并咪唑，其中取代基和符号具有描述中所示的含义。这些化合物具有抑制胃酸分泌和优异的胃肠保护作用特性。

  公开号：

  WO2004087701A1

文献信息

• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• Cyclic benizimidazoles
  申请人：Chiesa M. Vittoria

  公开号：US20060194968A1

  公开（公告）日：2006-08-31

  The invention relates to cyclic benzimidazoles of formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

  本发明涉及公式1中的环状苯并咪唑，其中取代基和符号具有说明书中所示的含义。该化合物具有抑制胃酸分泌和优异的胃肠保护作用性质。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• Syk inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10005774B2

  公开（公告）日：2018-06-26

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及作为 Syk 抑制剂的化合物及其在治疗各种疾病（包括癌症和炎症）中的用途。在特定的实施方案中，化合物的结构如式 I 所示： 其中 X1、X2、X3、R2、R3、R4、R5 和 Y 如本文所述。本公开进一步提供了包括式 I 的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由 Syk 介导的病症的方法。
• EP1613626A1
  申请人：——

  公开号：EP1613626A1

  公开（公告）日：2006-01-11